Abstract
Human umbilical cord blood (hUCB) is a primitive source of stem cells and is being banked worldwide for the purpose of future clinical use. Lineage negative (Lin-ve) stem cells are one of the primitive populations in hUCB which are capable of self-renewal and differentiation into multiple lineages. These cells have not been adequately investigated for their stem cell characteristics. We have analyzed the immunophenotypic expression of CD45, CD34 and CD117 markers on three different cell populations in hUCB viz., mononucleated cells (MNCs), Lineage positive (Lin+ve) and Lin-ve cells. The CD34 and CD117 expression was found to be 60 fold more in the Lin-ve population as compared to MNCs and Lin+ve cells. This expression was further enhanced in CD45+Lin-ve fraction. The CD34+ and CD117+ Lin-ve cells showed 99% positivity for CD45. Our data suggest that CD34+ CD117+ Lin-ve cells are reasonably enriched stem cell population in hUCB which can be clinically used for transplantation and other therapeutic purposes.
Keywords: CD117, CD34, haematopoietic, lineage, stem cell, umbilical cord blood.
Current Neurovascular Research
Title:An Enriched Population of CD45, CD34 and CD117 Stem Cells in Human Umbilical Cord Blood for Potential Therapeutic Regenerative Strategies
Volume: 11 Issue: 4
Author(s): Avijit Banik, Sudesh Prabhakar, Jasvinder Kalra and Akshay Anand
Affiliation:
Keywords: CD117, CD34, haematopoietic, lineage, stem cell, umbilical cord blood.
Abstract: Human umbilical cord blood (hUCB) is a primitive source of stem cells and is being banked worldwide for the purpose of future clinical use. Lineage negative (Lin-ve) stem cells are one of the primitive populations in hUCB which are capable of self-renewal and differentiation into multiple lineages. These cells have not been adequately investigated for their stem cell characteristics. We have analyzed the immunophenotypic expression of CD45, CD34 and CD117 markers on three different cell populations in hUCB viz., mononucleated cells (MNCs), Lineage positive (Lin+ve) and Lin-ve cells. The CD34 and CD117 expression was found to be 60 fold more in the Lin-ve population as compared to MNCs and Lin+ve cells. This expression was further enhanced in CD45+Lin-ve fraction. The CD34+ and CD117+ Lin-ve cells showed 99% positivity for CD45. Our data suggest that CD34+ CD117+ Lin-ve cells are reasonably enriched stem cell population in hUCB which can be clinically used for transplantation and other therapeutic purposes.
Export Options
About this article
Cite this article as:
Banik Avijit, Prabhakar Sudesh, Kalra Jasvinder and Anand Akshay, An Enriched Population of CD45, CD34 and CD117 Stem Cells in Human Umbilical Cord Blood for Potential Therapeutic Regenerative Strategies, Current Neurovascular Research 2014; 11 (4) . https://dx.doi.org/10.2174/1567202611666140902144836
DOI https://dx.doi.org/10.2174/1567202611666140902144836 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Analgesic and Anti-Inflammatory Properties of Arylnitroalkenes
Inflammation & Allergy - Drug Targets (Discontinued) Muscle Development and Regeneration in Normal and Pathological Conditions: Learning from Drosophila
Current Pharmaceutical Design Potential of Unengineered and Engineered Wharton’s Jelly Mesenchymal Stem Cells as Cancer Inhibitor Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research Neurotransmitters, Psychotropic Drugs and Microglia: Clinical Implications for Psychiatry
Current Medicinal Chemistry Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Medical Applications of Collagen and Collagen-Based Materials
Current Medicinal Chemistry Traumatic Brain Injury Altered Normal Brain Signaling Pathways: Implications for Novel Therapeutics Approaches
Current Neuropharmacology The Timing of Drug Administration for Thromboprophylaxis Following Orthopaedic Surgery: Evidence and Controversies Related to Treatment Initiation and Duration
Current Vascular Pharmacology An Overview of High-grade Glioma: Current and Emerging Treatment Approaches
Current Cancer Therapy Reviews Behcets Syndrome: Literature Review
Current Rheumatology Reviews Mechanically Activated Adipose Tissue as a Source for Novel Therapies in Neurological Disease/Injury
Current Stem Cell Research & Therapy Chronic Pain: Cytokines, Lymphocytes and Chemokines
Inflammation & Allergy - Drug Targets (Discontinued) Breakdown of Blood-Brain and Blood-Spinal Cord Barriers During Acute Methamphetamine Intoxication: Role of Brain Temperature
CNS & Neurological Disorders - Drug Targets Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets VIP-induced Neuroprotection of the Developing Brain
Current Pharmaceutical Design